推荐产品
等级
pharmaceutical primary standard
API类
risedronate
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
OP(C(P(O)([O-])=O)(O)CC1=CC=CN=C1)(O)=O.[Na+]
InChI
1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2
InChI key
HYFDYHPNTXOPPO-UHFFFAOYSA-L
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
Risedronate sodium is a member of the pyridinyl class of bisphosphonates. It is mostly used as an antiresorptive agent. It can be used in treating and preventing postmenopausal and glucocorticoid-induced osteoporosis.
应用
Risedronate sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Risedronate Sodium Tablets
- Risedronate Sodium Delayed-Release Tablets
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - STOT SE 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
CUNHA F.
American Journal of Surgery, 76(3), 244-260 (1948)
Eliska Vaculikova et al.
Molecules (Basel, Switzerland), 19(11), 17848-17861 (2014-11-07)
One approach for the enhancement of oral drug bioavailability is the technique of nanoparticle preparation. Risedronate sodium (Biopharmaceutical Classification System Class III) was chosen as a model compound with high water solubility and low intestinal permeability. Eighteen samples of risedronate
Yoshihisa Hirota et al.
PloS one, 10(4), e0125737-e0125737 (2015-04-16)
UbiA prenyltransferase domain-containing protein 1 (UBIAD1) plays a significant role in vitamin K2 (MK-4) synthesis. We investigated the enzymological properties of UBIAD1 using microsomal fractions from Sf9 cells expressing UBIAD1 by analysing MK-4 biosynthetic activity. With regard to UBIAD1 enzyme
Jin Woo Park et al.
Archives of pharmacal research, 37(12), 1560-1569 (2013-11-21)
Risedronate is widely used clinically to treat osteoporosis, Paget's disease, hypercalcemia, bone metastasis, and multiple myeloma. However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects. This study was designed to evaluate the effect
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门